Geron
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
919 E Hillsdale Blvd Ste 250, Foster Cit...Phone Number
(650) 473-7700Website
www.geron.comRevenue
$196.1 MillionStock Symbol
GERNIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Geron
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.Explore more
Geron Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Geron your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Geron
Check if Geron has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Geron recently announced quarterly report
Check out if Geron is spiking on competitors!
Funding: Get notified immidiatlly once Geron has new funding data
Product Launch: Get notified when Geron launches new products
Geron, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Geron had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Geron as Masked Content
Find more new buyers
Compare Similar Companies to Geron
Compare insights from companies similar to Geron, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Geron is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Geron is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Geron.
Geron financials insights
Gather financial insights about Geron, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
1996
Stock Offering
$16M
2020
Debt
$75M
2024
Debt
$375M
Geron Tech Stack
A closer look at the technologies used by Geron
See more technologies
Most Recent Scoops
Person-Based
Earnings, Finance
Person-Based
Person-Based
New Hire
Executive Move
Executive Moves, New Hire
Project
Laboratory Operations, Medical Research, Clinical Operations
Geron News & Media
Geron Corporation (GERN) Q2 2026 Earnings Call Transcript
Geron Corporation (GERN) Q2 2026 Earnings Call August 5, 2026 8:00 AM EDTCompany ParticipantsDawn Schottlandt - Senior Vice President of Investor Relations...Geron Q2 Earnings Call Highlights
Geron (NASDAQ:GERN) reported second-quarter net revenue of $57.5 million, up 17% from a year earlier and 11% sequentially, as the company continued to expand use of RYTELO among patients with lower-risk myelodysplastic syndromes, or MDS. Chief Executive Officer Harout Semerjian said first-half netGeron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Achieved $57.5 million in RYTELO® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase an aggregate of 202,500 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Geron
Sign Up For FreeTo access detailed company insights
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosi... Read More
